Efficacy of Ambroxol Combined with Loquat Syrup on Bacterial Pneumonia in Mice

Chenping Li,Zhi Chen,Jiaqi Shi,Xiuyun Zheng

DOI: https://doi.org/10.2147/jir.s478655

IF: 4.5

2024-12-01

Journal of Inflammation Research

Abstract:Chenping Li, Zhi Chen, Jiaqi Shi, Xiuyun Zheng Department of Pulmonary and Critical Care Medicine (PCCM), The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, People's Republic of China Correspondence: Xiuyun Zheng, Department of Pulmonary and Critical Care Medicine (PCCM), The First Affiliated Hospital of Wenzhou Medical University, 1210 University Town, Wenzhou, Zhejiang, People's Republic of China, Email Purpose: Bacterial pneumonia is a prevalent respiratory disease and a primary cause of death among hospitalized patients. Ambroxol and loquat syrup are widely utilized pharmaceuticals for managing respiratory infections in China. This study investigates the potential application and efficacy of combining ambroxol with loquat syrup for treating bacterial pneumonia. Methods: In this study, mice with P. aeruginosa-induced bacterial pneumonia were used to evaluate the therapeutic effects of ambroxol, loquat syrup, and their combination. A bacterial plate coating assay was performed to measure the P. aeruginosa content in saliva, lung tissue, and bronchoalveolar lavage fluid (BALF). A plate colony counting assay was conducted to assess the antibacterial activity of ambroxol and loquat syrup. Serum, BALF, and lung tissues were analyzed using qPCR, ELISA, immunohistochemistry, and hematoxylin-eosin staining to evaluate disease severity. Results: In this study, the experimental results demonstrate that, compared to treatment with ambroxol and/or loquat syrup alone, the combined administration of ambroxol and loquat syrup significantly increases the volume of saliva expectorated by mice infected with bacteria, concurrently augmenting bacterial presence in saliva while diminishing bacterial burden in the lungs, with significant differences observed ( p < 0.05). Furthermore, the combined therapy of ambroxol and loquat syrup achieved better therapeutic effects on P. aeruginosa pneumonia compared to ambroxol and/or loquat syrup alone ( p < 0.05), as evidenced by significantly reduced P. aeruginosa-induced lung injury, improved lung permeability, decreased inflammatory cell infiltration, and lower expression of inflammatory cytokines. Conclusion: These findings suggest that the combination therapy of ambroxol and loquat syrup presents a safe and feasible new treatment strategy for bacterial pneumonia, offering promising benefits for ameliorating lung tissue damage and inflammation. Keywords: bacterial pneumonia, ambroxol, loquat syrup, combination therapy, inflammation, treatment strategy Community-acquired pneumonia (CAP) is a common respiratory infection with an incidence of approximately 2% in adults worldwide, with at least half of CAP cases being attributed to bacterial pneumonia. 1,2 Evidence suggests that the severity of bacterial pneumonia varies based on the pathogen type and the host's immune status. 1,2 To date, antibiotics, such as penicillins, cephalosporins, macrolides, and fluoroquinolones, remain the primary treatment for bacterial pneumonia. 3 However, the emergence of antibiotic resistance, 4 particularly multidrug-resistance (MDR), significantly limits the clinical efficacy and options of antibiotics. 5 For example, β-lactam antibiotics are ineffective against methicillin-resistant Staphylococcus aureus (MRSA), and vancomycin fails to treat heteroresistant Staphylococcus aureus (hVISA) and vancomycin-intermediate Staphylococcus aureus (VISA). 4,5 Projections suggest that failure to overcome resistance in MDR Gram-negative bacteria-specific drugs could result in up to 10 million annual deaths due to antimicrobial resistance by 2050. 6,7 Consequently, guidelines emphasize the importance of drug susceptibility testing and, if necessary, combination antibiotic therapies, such as ceftolozane-tazobactam, ceftazidime-avibactam, and meropenem-vaborbactam. 8 Moreover, antibiotic treatment often entails numerous adverse effects, including an increased risk of diarrhea and colitis, as well as anaphylactic reactions and nephrotoxicity. 9,10 These challenges markedly heighten the complexity of treating bacterial pneumonia, underscoring the urgent need for innovative therapeutic approaches to address this pressing issue. Evidences suggest that traditional Chinese medicine exhibits a synergistic effect with conventional pneumonia therapy. 11,12 For example, certain plant extracts--such as epigallocatechin gallate from Camellia sinensis , 13 resveratrol primarily from Vitis vinifera , 14 and curcumin from Curcuma longa 15 --have been shown to enhance the antibacterial activity of antibiotics, 16 highlighting the f -Abstract Truncated-

immunology